 |
| Logo of Sinopharm Group Tongjitang (Guizhou) Pharmaceuticals Co Ltd |
Sinopharm Group Tongjitang (Guizhou) Pharmaceuticals Co Ltd (國藥集團同濟堂(貴州)制藥有限公司), a subsidiary of China National Pharmaceutical Group, is a state-owned high-tech enterprise that integrates planting, production, research and sales.
With a total registered capital of 249 million yuan ($37.6 million), the company is mainly engaged in research and development, and the manufacture and sale of modern Chinese medicines. Its businesses include production and sales of capsules, tablets, granules, powders, syrups, tinctures, oral solutions, decoctions, raw materials and other drugs.
It produces more than 140 kinds of Chinese and Western medicines. The Xianlinggubao Capsule, its leading product, is the sole Chinese patented medicine for osteoporosis, honored with the first prize for Scientific and Technology Progress Award from the World Federation of Traditional Chinese Orthopedics.
The company now has more than 2,000 employees. In 2016, the company realized a production value of 1.5 billion yuan.
